<VariationArchive VariationID="517592" VariationName="NM_000709.4(BCKDHA):c.511del (p.Leu171fs)" VariationType="Deletion" Accession="VCV000517592" Version="11" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-06-23" DateCreated="2018-04-09" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="497317" VariationID="517592">
      <GeneList>
        <Gene Symbol="BCKDHA" FullName="branched chain keto acid dehydrogenase E1 subunit alpha" GeneID="593" HGNC_ID="HGNC:986" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="41397818" stop="41425002" display_start="41397818" display_stop="41425002" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="41903693" stop="41930909" display_start="41903693" display_stop="41930909" Strand="+" />
          </Location>
          <OMIM>608348</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000709.4(BCKDHA):c.511del (p.Leu171fs)</Name>
      <CanonicalSPDI>NC_000019.10:41419156:CCCCC:CCCC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="41419157" stop="41419157" display_start="41419157" display_stop="41419157" variantLength="1" positionVCF="41419156" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="41925062" stop="41925062" display_start="41925062" display_stop="41925062" variantLength="1" positionVCF="41925061" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>L171fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.41419161del" Assembly="GRCh38">
            <Expression>NC_000019.10:g.41419161del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.41925066del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.41925066del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_013004.1" sequenceAccession="NG_013004" sequenceVersion="1" change="g.26373del">
            <Expression>NG_013004.1:g.26373del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000709.4" sequenceAccession="NM_000709" sequenceVersion="4" change="c.511del" MANESelect="true">
            <Expression>NM_000709.4:c.511del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000700.1" sequenceAccession="NP_000700" sequenceVersion="1" change="p.Leu171fs">
            <Expression>NP_000700.1:p.Leu171fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001164783.2" sequenceAccession="NM_001164783" sequenceVersion="2" change="c.511del">
            <Expression>NM_001164783.2:c.511del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001158255.1" sequenceAccession="NP_001158255" sequenceVersion="1" change="p.Leu171fs">
            <Expression>NP_001158255.1:p.Leu171fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA9461189" DB="ClinGen" />
        <XRef Type="rs" ID="762084007" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000709.4(BCKDHA):c.511del (p.Leu171fs) AND Maple syrup urine disease" Accession="RCV000601066" Version="11">
        <ClassifiedConditionList TraitSetID="6467">
          <ClassifiedCondition DB="MedGen" ID="C0024776">Maple syrup urine disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-10-26" SubmissionCount="3">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000709.4(BCKDHA):c.511del (p.Leu171fs) AND Maple syrup urine disease type 1A" Accession="RCV004568334" Version="1">
        <ClassifiedConditionList TraitSetID="9391">
          <ClassifiedCondition DB="MedGen" ID="C1855369">Maple syrup urine disease type 1A</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-01" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2018-04-09" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16786533</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22593002</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31980395</ID>
        </Citation>
        <DescriptionHistory Dated="2018-10-10">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="6467" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2822" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Maple syrup urine disease</ElementValue>
                <XRef ID="Maple+syrup+urine+disease/4453" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009563" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS248600" DB="OMIM" />
                <XRef ID="511" DB="Orphanet" />
                <XRef ID="27718001" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MSUD</ElementValue>
                <XRef Type="MIM" ID="248600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Maple syrup urine disease (MSUD) is categorized as classic (severe), intermediate, or intermittent. Neonates with classic MSUD are born asymptomatic but without treatment follow a predictable course: 12â€“24 hours. Elevated concentrations of branched-chain amino acids (BCAAs; leucine, isoleucine, and valine) and alloisoleucine, as well as a generalized disturbance of amino acid concentration ratios, are present in blood and the maple syrup odor can be detected in cerumen; Two to three days. Early and nonspecific signs of metabolic intoxication (i.e., irritability, hypersomnolence, anorexia) are accompanied by the presence of branched-chain alpha-ketoacids, acetoacetate, and beta-hydroxybutyrate in urine; Four to six days. Worsening encephalopathy manifests as lethargy, apnea, opisthotonos, and reflexive "fencing" or "bicycling" movements as the sweet maple syrup odor becomes apparent in urine; Seven to ten days. Severe intoxication culminates in critical cerebral edema, coma, and central respiratory failure. Individuals with intermediate MSUD have partial branched-chain alpha-ketoacid dehydrogenase deficiency that manifests only intermittently or responds to dietary thiamine therapy; these individuals can experience severe metabolic intoxication and encephalopathy in the face of sufficient catabolic stress. In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed neonatal manifestations of MSUD remain asymptomatic with continued treatment compliance.</Attribute>
                <XRef ID="NBK1319" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3228" />
                <XRef ID="3228" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000505125" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528449" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521391" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505096" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592960" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519087" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529111" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301495</ID>
                <ID Source="BookShelf">NBK1319</ID>
              </Citation>
              <Citation Type="general" Abbrev="GMDI/SERC, 2014">
                <ID Source="PubMed">24881969</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="GMDI/SERN, 2021">
                <URL>https://managementguidelines.net/guidelines.php/129/MSUD%20Nutrition%20Guidelines/Version%201.58</URL>
                <CitationText>MSUD Nutrition Management Guidelines</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2021">
                <URL>https://www.acmg.net/PDFLibrary/Leucine.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Leucine, Maple Syrup Urine Disease, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2021">
                <URL>https://www.acmg.net/PDFLibrary/Leucine-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Leucine Elevated, 2021</CitationText>
              </Citation>
              <XRef ID="511" DB="Orphanet" />
              <XRef ID="C0024776" DB="MedGen" />
              <XRef ID="D008375" DB="MeSH" />
              <XRef ID="MONDO:0009563" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS248600" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9391" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9026" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Maple syrup urine disease type 1A</ElementValue>
                <XRef ID="Maple+syrup+urine+disease+type+1A/4455" DB="Genetic Alliance" />
                <XRef ID="MONDO:0023691" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MSUD type 1A</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MSUD1A</ElementValue>
                <XRef Type="MIM" ID="248600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8594" />
                <XRef ID="8594" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301495</ID>
                <ID Source="BookShelf">NBK1319</ID>
              </Citation>
              <XRef ID="C1855369" DB="MedGen" />
              <XRef ID="MONDO:0023691" DB="MONDO" />
              <XRef Type="MIM" ID="248600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1413110" SubmissionDate="2019-03-21" DateLastUpdated="2018-04-09" DateCreated="2018-04-09">
        <ClinVarSubmissionID localKey="82818114|Orphanet:ORPHA511" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000731950" DateUpdated="2018-04-09" DateCreated="2018-04-09" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-10-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The p.Leu171TrpfsX159 (NM_000709.3 c.511delC) variant in BCKDHA has not been pre viously reported in individuals with maple syrup urine disease. It has been iden tified in 3/30782 South Asian chromosomes by the Genome Aggregation Database (ht tp://gnomad.broadinstitute.org; rs762084007). This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at posit ion 171 and leads to a premature termination codon 159 amino acids downstream. T his alteration is then predicted to lead to a truncated or absent protein. Biall elic loss of function of the BCKDHA gene is associated with maple syrup urine di sease. In summary, although additional studies are required to fully establish a null impact, the p.Leu171TrpfsX159 variant is likely pathogenic for maple syrup urine disease in an autosomal recessive manner based on its predicted impact on the protein. ACMG/AMP Criteria applied: PVS1; PM2 (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BCKDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000709.3:EXON 5</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>NM_000709.3:c.511delC</Name>
            <Name>p.Leu171TrpfsX159</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.41925066delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA511" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5348977</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3988733" SubmissionDate="2021-12-15" DateLastUpdated="2021-12-18" DateCreated="2021-12-18">
        <ClinVarSubmissionID localKey="NM_000709.4:c.511del|OMIM:248600" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002033384" DateUpdated="2021-12-18" DateCreated="2021-12-18" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BCKDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000709.4:c.511del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="248600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10805773</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1592236" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="3868503|MedGen:C0024776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000819977" DateUpdated="2024-02-14" DateCreated="2018-10-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16786533</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22593002</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31980395</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Leu171Trpfs*159) in the BCKDHA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BCKDHA are known to be pathogenic (PMID: 16786533, 22593002). This variant is present in population databases (rs762084007, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with maple syrup urine disease (PMID: 31980395). ClinVar contains an entry for this variant (Variation ID: 517592). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BCKDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.41925062del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0024776" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB4474525</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7862107" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000709.4:c.511del|OMIM:248600" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004215916" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000709.4:c.511del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="248600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1413110" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA511" MappingRef="Orphanet">
        <MedGen CUI="C0024776" Name="Maple syrup urine disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3988733" TraitType="Disease" MappingType="XRef" MappingValue="248600" MappingRef="OMIM">
        <MedGen CUI="C1855369" Name="Maple syrup urine disease type 1A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7862107" TraitType="Disease" MappingType="XRef" MappingValue="248600" MappingRef="OMIM">
        <MedGen CUI="C1855369" Name="Maple syrup urine disease type 1A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1592236" TraitType="Disease" MappingType="XRef" MappingValue="C0024776" MappingRef="MedGen">
        <MedGen CUI="C0024776" Name="Maple syrup urine disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

